UPDATED: Middle-of-the-night NIH statement raises concerns on AstraZeneca's US vaccine trial readout
The NIH took the very unusual step to release a statement at midnight, raising fresh questions about data from AstraZeneca’s US-based Covid-19 vaccine trial.
The statement says that late Monday, the Data and Safety Monitoring Board (DSMB) overseeing the trial notified the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and AstraZeneca “that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.